Check for updates

OPEN ACCESS

EDITED BY Kim Cornelia Marie-Louise Bul, Coventry University, United Kingdom

REVIEWED BY

Erik Hoencamp, University Department Psychology, Netherlands Karin Waldherr, Ferdinand Porsche FernFH—Distance Learning University of Applied Sciences, Austria

*CORRESPONDENCE Karolina Morello ⊠ karolina.morello@lir-mainz.de

[†]These authors share last authorship

RECEIVED 05 July 2023 ACCEPTED 09 October 2023 PUBLISHED 20 October 2023

CITATION

Morello K, Schäfer SK, Kunzler AM, Priesterroth L-S, Tüscher O and Kubiak T (2023) Cognitive reappraisal in mHealth interventions to foster mental health in adults: a systematic review and meta-analysis. Front. Digit. Health 5:1253390. doi: 10.3389/fdgth.2023.1253390

COPYRIGHT

© 2023 Morello, Schäfer, Kunzler, Priesterroth, Tüscher and Kubiak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Cognitive reappraisal in mHealth interventions to foster mental health in adults: a systematic review and meta-analysis

Karolina Morello^{1*}, Sarah K. Schäfer^{1,2}, Angela M. Kunzler^{1,3}, Lilli-Sophie Priesterroth⁴, Oliver Tüscher^{1,5,6†} and Thomas Kubiak^{4†}

¹Leibniz Institute for Resilience Research (LIR) Mainz, Mainz, Germany, ²Clinical Psychology, Psychotherapy and Diagnostics, Technische Universität Braunschweig, Brunswick, Germany, ³Institute for Evidence in Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁴Health Psychology, Institute of Psychology, Johannes Gutenberg University Mainz, Mainz, Germany, ⁵Department of Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg University Mainz, Germany, ⁶Institute of Molecular Biology (IMB), Mainz, Germany

Background: An increasing number of mHealth interventions aim to contribute to mental healthcare of which interventions that foster cognitive reappraisal may be particularly effective.

Objectives: To evaluate the efficacy of mHealth interventions enhancing cognitive reappraisal to improve mental health in adult populations.

Methods: The literature search (four databases) yielded 30 eligible randomized controlled trials (comprising 3,904 participants). We performed a multi-level meta-analysis to examine differences between intervention and comparator conditions at post-intervention assessment. Moderator analyses were conducted for potential moderator variables (e.g., type of comparators).

Results: Most interventions were CBT-based with other training components in addition to cognitive reappraisal. We found preliminary evidence for a small to medium effect favouring mHealth interventions to enhance cognitive reappraisal over comparators, M(SMD) = 0.34, p = .002. When analysing single symptoms, there was evidence for a small to medium effect of mHealth interventions on anxiety and depressive symptoms, but not for psychological distress and wellbeing. All analyses showed substantial heterogeneity. Moderator analyses revealed evidence for more favourable effects in studies with passive comparators. There was an overall high risk of bias in most of the studies.

Conclusions: We found preliminary evidence for a small to medium effect of mHealth interventions including a cognitive reappraisal component to improve mental health. However, most of the interventions were complex (i.e., reappraisal was provided alongside other components), which prevents us from examining reappraisal-specific effects beyond general mental health promotion in mHealth. Dismantling studies examining the effects of single intervention components are warranted to corroborate these promising results.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ display_record.php?RecordID=142149, identifier [CRD42019142149].

KEYWORDS

mHealth, mental health apps, ecological momentary intervention, mental health, reappraisal, cognitive restructuring, systematic review, meta-analysis

Introduction

The high prevalence of mental disorders is a key challenge for healthcare (1). Digital technologies such as mobile phones can potentially improve the dissemination of evidence-based mental health interventions (2, 3). Thus, numerous mobile-based programs, also referred to as mobile health (mHealth) interventions, were developed and distributed in the last years. These aim at improving mental health and well-being or reducing symptoms of mental disorders of their users. Using mobile apps, trainings can easily be delivered to users in their everyday lives and natural settings in a timely fashion (4).

mHealth apps can be implemented as stand-alone interventions, that might also be used as easy-to-access self-help programs. Alternatively, mHealth can be used as an add-on to face-to-face treatments, e.g., for therapeutic guidance (2). Thus, mHealth is an easily accessible, low-cost method that has the potential to help overcoming supply gaps in mental healthcare (5, 2, 6).

A number of clinical trials as well as recent systematic reviews and meta-analyses pointed to an increasing importance of mHealth interventions for mental health care and promotion (3, 7-12). Those studies provided evidence for mHealth interventions being feasible, acceptable, and effective in different populations and for different purposes. In line with common classifications (13, 14), mHealth interventions can be used in the following domains: First, many mHealth interventions aim at reducing symptoms of mental disorders (i.e., treatment) such as anxiety disorders and depression (15-18, 11). However, not only patients with manifest mental disorders can be targeted by mHealth interventions. For at-risk groups, subpopulations, or the general community mHealth interventions may also have the potential to prevent mental disorders [i.e., prevention (19)] or to promote positive aspects of functioning and well-being [i.e., mental health promotion (20)]. Research focuses primarily on mHealth interventions, which aim at reducing symptoms of mental disorders (21, 9), but there is some evidence on the effects of mHealth interventions for the general community (22, 20) which highlights the benefits for a broader target group.

The increasing popularity of mHealth interventions to reduce symptoms of mental illness as well as to promote mental health claims for their critical evaluation to provide users with effective and safe technologies. However, the scientific evaluation of mHealth trainings is still in its beginnings and the integration of scientifically validated theories and strategies into mHealth interventions in order to maximize a favorable mental health impact often remains unclear (23-25). For example, a recent systematic review examined the extent to which evidence-based contents are included in popular smartphone apps for the treatment of depression and anxiety (26). The study found that most of these apps included at least one evidence-based treatment element. However, specific evidencebased components were found rarely in those apps. Thus, there is evidence for a gap between empirically supported treatment components and the components used in mHealth

interventions (26). Moreover, it becomes apparent that many mHealth interventions are multi-component interventions (27). They offer a range of components in combination with each other, of which some are evidence-based whereas others are not, which further complicates a statement on the effectiveness of single components.

One of the above-mentioned evidence-based intervention components is cognitive reappraisal, which pertains to modify dysfunctional thoughts. Cognitive reappraisal is an emotion regulation strategy that has been defined as creating alternative appraisals or interpretations of a potentially emotion-eliciting situation to change its emotional impact (28–30). As a strategy of cognitive change, reappraisal can be achieved through techniques of cognitive restructuring, reframing or reinterpretation, which represent key tactics of cognitive behavioral therapy [CBT (31, 32)].

Evidence comes from meta-analyses on the impact of reappraisal on mental health: Cognitive reappraisal has been found to be negatively correlated with symptoms of mental distress (33–36) and positively with indicators of mental health such as well-being (37, 35). Moreover, reappraisal appears to be associated with successful coping and maintaining of well-being when facing stressful events [i.e., resilience (38)]. Therefore, cognitive reappraisal might be a valuable ingredient for all types of mHealth interventions (treatment, prevention, or mental health promotion).

It is well established that reappraisal processes play a central role in the development and maintenance of mental illness, as changing dysfunctional cognitions is essential to reduce symptoms of mental disorders (31). Following a mechanistic approach, reappraisal might be seen as an active therapeutic mechanism. This means, that an effective psychological treatment might enhance reappraisal skills of an individual, which in turn contributes to symptom change (39). In line with this notion, there is evidence from CBT-based interventions that changes in symptom-related cognitions (i.e., reappraisal) mediate changes in symptoms, for example of panic disorder (40) and post-traumatic stress disorder [PTSD (41)].

On the other hand, research on the specific effects of reappraisal components in CBT interventions is still ongoing. Some mixed evidence is coming from research on the effectiveness of specific intervention components in complex CBT interventions. While some studies found no evidence for specific effects of any components (42) or no additive effect of reappraisal-related components (43, 44), Pompoli et al. (45) found that cognitive restructuring components are associated with the largest remission rates in panic disorder.

Notably, this research on reappraisal components does not focus the setting of mHealth interventions. Therefore, it remains unclear whether the advantages of mHealth, such as facilitating a continuous training of cognitive reappraisal in everyday life at a time, when a person needs support, can be put into practice.

Therefore, this systematic review and meta-analysis aims to examine the efficacy of psychological mHealth interventions comprising a component of cognitive reappraisal to enhance mental health in clinical and non-clinical adult populations.

Methods

A review protocol was registered with PROSPERO (ID: CRD42019142149). The review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Metaanalysis [PRISMA (46)]. We used the web-based platforms Covidence (47) and Rayyan (48) for the screening process.

Search strategy

A comprehensive literature search in MEDLINE (via PubMed), PsycArticles (via Ebscohost), Embase (via Ovid) and CENTRAL was conducted (search starting from the incept of each database; last update: March 7, 2022). The search process for this review integrated search terms for several higher-level resilience mechanisms identified in a landmark theory paper [(49); i.e., cognitive reappraisal, cognitive flexibility, extinction learning, interference inhibition, and stress immunization]. Of these resilience mechanisms, only cognitive reappraisal is relevant for the present review. Records addressing other resilience mechanisms than cognitive reappraisal were excluded throughout the process of study selection to ensure sufficient comparability of the included studies. The search strategy comprised four clusters of search terms that were searched in title, abstracts and (partly) in keywords: (1) cognitive reappraisal (e.g., cognitive restructuring, emotion regulation); (2) intervention (e.g., training, program); (3) mobile delivery [e.g., ecological momentary intervention (EMI), mobile application] and (4) study design [e.g., randomized controlled trial (RCT)]. Within clusters, search terms were combined using the Boolean operator OR, while clusters were linked using the operator AND. The search strategies for all databases are presented in Supplementary Material A.

Study selection

All identified records were screened by two independent reviewers. First, clearly irrelevant records were excluded at title/ abstract level. Second, eligibility was assessed at full-text level (kappa = .65), where we examined whether the mHealth interventions contained at least one reappraisal-enhancing component. For this purpose, we retrieved additional materials (i.e., study protocols, websites, app store or play store entries) related to the respective mHealth interventions, to gather information on intervention components. Discrepancies were resolved through discussion or by consulting a third author at each stage, and consensus was achieved in all cases.

Eligibility criteria

Studies were eligible if they met the following criteria: (a) An adult study sample (\geq 18 years) from a clinical or non-clinical

population was assessed. (b) The intervention used mobile devices (e.g., smartphones, tablets) to deliver intervention components to participants in their everyday lives. We considered stand-alone mHealth interventions as well as interventions that included a mobile component as an adjunct to other delivery formats (e.g., face-to-face). The examined interventions did have to address cognitive reappraisal and provide related techniques (e.g., cognitive restructuring; see Supplementary Material B for more information). (c) Included studies were RCTs, controlled trials (CTs), or cluster-randomized trials with a comparison of the mHealth intervention against any control group (e.g., wait-list control, no treatment control) or any other treatment not comprising a cognitive reappraisal component (e.g., face-to-face intervention, treatment as usual, other mHealth intervention). (d) The studies assessed at least one mental health outcome (primary outcome), that is, depressive symptoms and anxiety symptoms, measures of general psychological distress, and well-being outcomes (e.g., quality of life). Secondary outcome was cognitive reappraisal. We considered results of self-reported questionnaires, for example the Patient Health Questionnaire [PHQ-9 (50)] for depression, or the Cognitive Emotion Regulation Questionnaire [CERQ (51)] for cognitive reappraisal, and clinician-administered interviews. (e) Eligible studies were peer-reviewed publications published in English.

Data extraction and coding

Two independent reviewers extracted relevant information of the included studies using a predefined data extraction sheet. The following information were extracted: (a) study details (e.g., first author, publication year, country); (b) sample characteristics (e.g., sample size, mean age, gender balance); (c) intervention characteristics (e.g., name of the mHealth intervention, intervention length, availability of human support, proportion of cognitive reappraisal); (d) study methods (e.g., design, type of comparator); (e) mental health outcomes and measures.

For all included studies, we defined relevant intervention arms and outcome measures. Arms comprising a mHealth intervention with a cognitive reappraisal component were defined as intervention group; other arms were defined as comparators. For each study, all reported outcomes of interest for these meta-analyses were considered. More details on data extraction and coding (e.g., definition of availability of human support, intervention type, intervention triggering as well as proportion of cognitive reappraisal) are presented in **Supplementary Material B**.

Quality and bias assessment

Risk of bias of primary studies

As only RCTs were identified, risk of bias was assessed independently and in duplicate in the following domains using the Cochrane Risk of Bias Assessment Tool 2 [RoB2 (52)]: (a)

bias arising from the randomization process; (b) bias due to deviations from intended interventions; (c) bias due to missing outcome data; (d) bias in measurement of the outcome; and (e) bias in selection of the reported result. With one identified crossover RCT, we proceeded according to the additional considerations for crossover trials of the RoB2 tool. In addition to bias ratings per domain, the overall risk of bias was assessed at study level. Ratings could be "low" or "high" risk of bias or express "some concern" (52). The interrater agreement was high (96.2%), and all disagreements were resolved through discussion.

Publication bias

The potential impact of publication bias was examined by using visual inspections of contour-enhanced funnel plots (53) as well as by means of statistical analyses by approximating the Begg Mazumdar rank correlation test (54). This test is not available for multilevel meta-analysis but can be approximated by including the sampling error as moderator variable to the main analysis. In case the sampling error would significantly predict study effect sizes, this can be interpreted as evidence of a nonnormal distribution of effect sizes and thus, suggest the presence of a publication bias.

Data synthesis

Included studies were summarized narratively and in tabular form. Pairwise meta-analyses (intervention vs. comparator) were performed for primary outcomes if at least two studies were available, and these were sufficiently homogeneous in terms of intervention types and outcomes. For studies with multiple intervention arms, it was determined which arm was most relevant for this review. In case more than one arm was relevant, these were averaged according to the recommendations of the Cochrane Collaboration (55). For our meta-analyses, we included multiple types of comparators (e.g., wait-list and active controls, face-to-face interventions). However, we examined the impact of this analytical decision by means of subgroup moderator analyses. In case data needed for effect size calculation was missing or ambiguous, study authors were contacted by the review team.

All statistical analyses were performed in R version 4.2.3 (56) using the package *metafor* (57). As we expected relevant between-study heterogeneity, all analyses used random-effects models and maximum likelihood estimations.

As effect size measure, we used standardized mean differences (SMDs, Hedges' g) at post-intervention assessment and 95% confidence intervals (CIs) as indicators of their significance. SMDs were calculated based on the means, standard deviations (SDs), or alternative statistical information (e.g., standard error), with positive SMDs indicating a favorable effect of the intervention over the comparator condition (i.e., better mental health at post-intervention assessment). Moreover, as we expected to find heterogeneous results, 95% prediction intervals (PIs) were used to account for uncertainty of meta-analytical findings (55). PIs provide an estimate of the interval in which 95% of future observations will fall. In line with previous

recommendations, PIs were calculated when 10 or more effect sizes were available per analysis (55).

Our main analysis aimed at answering the question of whether there is an effect of mHealth interventions aiming to enhance cognitive reappraisal on overall mental health. For this purpose, we used a multilevel approach nesting effect sizes of mental health indicators defined as primary outcomes within studies and outcome types [i.e., depressive symptoms and anxiety symptoms, measures of general psychological distress, and well-being (58)]. Thereby, our model allowed for correlations of effect sizes coming from the same study as well as for correlations of effect sizes coming from different studies but assessing the same outcome type (e.g., depressive symptoms).

If a study used more than one questionnaire to assess an outcome domain, for example the PHQ-9 and BDI-II (59) for depressive symptoms, we used the questionnaire that was administered most frequently across all studies in our analyses. In the few cases, where outcome data were available for more than one time point after the end of intervention, data of the post-intervention assessment was used to ensure between-study comparability.

Additional analyses aimed at answering the question of whether there is an effect of mHealth interventions aiming to enhance cognitive reappraisal on specific symptom types (e.g., depressive symptoms) or mental well-being. For these analyses, we used traditional meta-analyses for all primary outcomes.

Statistical heterogeneity was assessed using the Cochran's Q statistic (60), with a significant Q statistic indicating the presence of heterogeneity. To further describe the amount of heterogeneity in our analyses, we used the I^2 statistics (range: 0%–100%), with values of 50% and above indicating substantial heterogeneity (55). As part of our multilevel approach, we estimated heterogeneity related to between-study and between-outcome differences separately (58).

We had planned several moderator analyses in advance (see preregistration: CRD42019142149), which were also conducted due to the substantial heterogeneity as indicated by the abovementioned indicators. All moderator analyses were performed using the multilevel approach of our primary analysis. We used meta-regressions for moderator analyses, that is, omnibus moderation tests (Q_M) for categorical moderators (e.g., type of comparator) and to examine the impact of continuous moderators (e.g., sample mean age), with a significant Q_M test indicating the presence of a moderator effect. In case of categorical moderators, we obtained subgroup estimates from the multilevel model. Moderator analyses were performed for sociodemographic sample characteristics (i.e., mean sample age, and proportion of female participants), year of publication, population type (clinical vs. nonclinical population), proportion of cognitive reappraisal enhancing components, intervention duration, intervention type (treatment vs. prevention vs. mental health promotion), availability of human support, stand-alone mHealth interventions vs. combined interventions (e.g., mHealth intervention with face-to-face sessions) and comparator type (passive vs. active control condition).

Sensitivity analyses were performed based on the multilevel model used for primary analysis and examined the impact of risk of bias (only for risk of bias domains with sufficient between-study variation), the inclusion of a crossover RCT for which no ideal outcome data was available, and the impact of considering studies in which the cognitive reappraisal condition was defined as control condition by primary study authors.

Results

The literature search yielded 2,502 records after duplicates had been removed for title/abstract screening (see **Figure 1**). Of these records, 266 were assessed on the full-text level. Full-text level screenings resulted in 30 studies (from 34 reports) that were eligible for the review and included in the qualitative and quantitative summary.


Study characteristics

Supplementary Material C provides an overview of the characteristics of the 30 studies [corresponding to 34 reports

(61–95)] comprising a total of 5,377 participants at baseline (n_{IG} = 2,697, n_{CG} = 2,680). All studies were RCTs, including one crossover RCT (72). They were all published recently (between 2014 and 2022). Ten studies were conducted in the United States, five in Germany, three were from the Republic of Korea, two from Iran and two from China, with the remaining studies being from Canada, Australia, Japan, South Africa, Sweden, Switzerland, Vietnam, and the United Kingdom.

The mean age of the participants ranged from 18.68 to 74.93 years. The mean percentage of female participants across all studies was 68.51% (*SD* = 18.64) indicating an overrepresentation of female participants. Most studies assessed non-clinical and/or sub-clinical samples (n = 20), whereas samples of 10 studies were clinical (i.e., referred to as patients).

Nevertheless, also in non-clinical samples, most of the participants showed elevated symptoms of mental disorders (15 out of 20 non-clinical samples) but were not referred to as patients in a clinical setting and therefore classified as non-clinical. In total, participants of 23 out of 30 studies showed at least some elevated mental health symptoms. Sixteen studies



10.3389/fdgth.2023.1253390

assessed participants with depressive symptoms, nine studies reported on samples with anxiety or trauma-related symptoms, and one study examined patients with schizophrenia, schizoaffective disorder or bipolar I disorder (69). Six studies reported on samples with somatic diseases, which were the human immunodeficiency virus [HIV (94) epilepsy (61, 86), irritable bowel syndrome (72), and cancer (70, 71)]. Two studies assessed samples without any somatic or mental disease (63, 77). In line with the notion that most samples showed symptoms of mental disorders, the majority of studies (*n* = 23) mostly aimed at reducing mental symptoms. Five studies were prevention interventions and two studies focused on the promotion of mental health. Most studies primarily aimed at reducing depressive symptoms. Intervention duration ranged from 14 to 112 days (*M* = 54.57, *SD* = 26.63).

All mHealth interventions used smartphones and/or apps. For some interventions, materials could alternatively be accessed via computer or tablet, if preferred (66, 74, 86, 90). Within the mHealth interventions, the full range of multimedia materials was presented: Interventions used text-based elements combined with other materials like voice mails (77), cartoons (81, 96), interactive games (97, 90), and video material (66, 70). In addition to educational intervention elements, all studies required active engagement from the participants. Active engagement was facilitated by various types of interaction with the app or the study personnel, for example, diary entries of negative beliefs (93), multistep questions (73, 81), rating scales (69), or games (90). Some studies were based on messenger apps (94), or integrated a chatbot (89). The majority of studies (n = 22) did not provide human support in addition to the mHealth intervention, while in eight studies human guidance or feedback was available. Moreover, most mHealth interventions (n = 23) were established in a stand-alone manner without non-mHealth components. Most studies (n = 14)delivered the intervention components on-demand, that is, the training was available at any time throughout the study period. Another five mHealth interventions prescribed a fixed schedule for usage (e.g., three exercises per day) and one intervention triggered participants (i.e., prompts to engage in exercises). Ten studies used a combination of on-demand, fixed and triggered delivery.

Most studies (n = 23) evaluated the mHealth interventions against a passive comparator (i.e., wait-list, treatment as usual, no intervention), whereas 14 studies used active comparators, with most studies using a comparable mobile app with educational material as active comparator. Seven studies assessed both, a passive as well as an active control group.

Three studies (81, 77, 69) used clinician-administered interviews for outcome assessment whereas the outcomes of the remaining studies were self-reported. Depressive symptoms were assessed in the majority of studies (n = 27). Nineteen studies reported on anxiety symptoms, 14 studies on well-being, and two on general psychological distress.


Implementation of cognitive reappraisal


All interventions were theoretically based on cognitive behavioral therapy (CBT), cognitive theory (92), or cognitive behavioral stress management [CBSM, (94)]. Most of the identified mHealth interventions (n = 27) were multi-component interventions, meaning that cognitive reappraisal was promoted alongside other training components (e.g., behavioral activation). There were three studies (67, 73, 92) solely focusing on cognitive reappraisal. **Supplementary Material D** gives an overview of the components of each study as well as the relative importance of the cognitive reappraisal component in relation to the full intervention. The proportion of cognitive reappraisal in the interventions was relatively low (M = 28.27%, SD = 25.21).

Study quality

Risk of bias

There was an overall high risk of bias in 27 of 30 studies (see Figure 2 and Supplementary Material E). Main flaws ($\geq 20\%$ some concerns or high-risk ratings) across the included studies and outcomes came from outcome measurement (89.7%, i.e., most studies used self-report measures for outcome assessment and participants were not blinded), deviations from





intended interventions (53.3%), and missing outcome data (36.7%). For the study with a crossover design (72), risk of bias arising from period and carryover effects was low.

Publication bias

The meta-regression model provided evidence for a trend towards an association of sample errors and effect size estimates for the main analysis, $Q_M(1) = 3.20$, p = .074, that is, the effect sizes are likely to violate the assumption of a normal distribution. The visual inspection of the contour-enhanced funnel plot suggested the presence of a mild publication bias (see **Figure 3**), with effect sizes being more likely to fall into the right significant border area of the funnel plot, while the number of studies in non-significant areas was smaller.

Pairwise meta-analysis-intervention effect

Thirty studies [comprising 62 effect sizes from 9,458 observations of 3,904 participants (intervention: 4,692 observations from 1,881 participants; comparators: 4,766 observations from 2,023 participants)] were included in our quantitative synthesis (see Figure 4). Using a multilevel approach, we compared postintervention means across all mental health outcomes between mHealth interventions to enhance cognitive reappraisal and any comparator condition. Moreover, we examined group differences of post-intervention means for single mental health indicators (see Table 1). Across all mental health outcomes, we found evidence for a small to medium effect favouring mHealth interventions to enhance cognitive reappraisal over comparators, M(SMD) = 0.34, 95% CI [0.12, 0.56], p = .002, with considerable heterogeneity between studies and mental health outcomes, Q(61) = 295.42, p <.001; $I^2 = 86.5\%$. However, the majority of the total heterogeneity was accounted for by between-study differences ($I^2 = 78.5\%$), while only 8.0% originated from between-outcome differences. The presence of considerable heterogeneity was further supported by the wide 95% PI covering small to medium adverse and large favourable intervention effects.

When analysing single symptoms, there was evidence for a small to medium effect of mHealth interventions to enhance cognitive reappraisal on anxiety symptoms, M(SMD) = 0.33, 95% CI [0.16, 0.50], p = .001, and depressive symptoms, M(SMD) = 0.51, 95% CI [0.30, 0.73], p = <.001. However, there was no evidence in favour of mHealth interventions to enhance cognitive reappraisal for psychological distress, M(SMD) = 0.20, 95% CI [-0.25, 0.66], p = .380, and well-being, M(SMD) = 0.18, 95% CI [-0.05, 0.42], p = .126. Overall, between-study heterogeneity was considerable for all analyses ($I^2 \ge 76.7\%$) except for the meta-analysis on psychological distress ($I^2 = 60.6\%$), however, this was based on only two studies.

Moderator analyses

Moderator analyses were performed for the main analysis comprising all mental health outcomes.

Sociodemographic variables

We found no evidence for a moderating effect of mean sample age, $Q_M(1) = 1.34$, p = .247, and proportion of female participants per sample, $Q_M(1) = 0.15$, p = .698.

Year of publication

We found no evidence for an association of publication year and effect size estimates, $Q_M(1) = 0.01$, p = .907, that is, more recent mHealth interventions were not associated with larger effects.

Population type

We found no evidence for differences between intervention effects in clinical (i.e., patients) and non-clinical populations,

Study	Symptom Category					Stan	dardized Me	ean Difference [95% Cl
Stolz 2018	Anxiety symptoms			:	-			1.91 [1.31, 2.5
lur 2018	Anxiety symptoms			<u>}</u>	• · · · ·			0.74 0.04, 1.4
agöö 2014	Anxiety symptoms			: -	—			0.63 0.24, 1.0
horsu 2020	Anxiety symptoms			: +-				0.51 [0.29, 0.1
eyer 2019	Anxiety symptoms			:	-			0.50 0.22, 0.3
unt 2021	Anxiety symptoms			F .	-			0.40 [-0.05, 0.1
oberg 2019	Anxiety symptoms			:				0.36 [0.07, 0.0
ewman 2021	Anxiety symptoms			H; •	-			0.31 [-0.12, 0.1
u 2022	Anxiety symptoms			⊢ ;	-			0.30 [-0.14, 0.1
h 2020	Anxiety symptoms			H				0.30 [-0.32, 0.9
uehlman-Senecal 2020	Anxiety symptoms							0.26 [-0.01, 0.9
cCloud 2020	Anxiety symptoms			H	S 65			0.22 [-0.18, 0.0
reer 2019	Anxiety symptoms				_			0.21 [-0.60, 1.0
-Refae 2021	Anxiety symptoms							0.19 [-0.14, 0.9
amura 2021	Anxiety symptoms			HEH				0.14 [-0.00, 0.1
pepke 2015	Anxiety symptoms							0.13 [-0.38, 0.0
5hr 2021	Anxiety symptoms		1/2					0.09 [-0.26, 0.4
am 2019 akker 2018	Anxiety symptoms							-0.09 [-0.62, 0.4
	Anxiety symptoms		-	-				-0.32 [-0.64, -0.0
E Model (Q = 61.38, df = 1	$18, p < .01; l^{-} = 76.7\%$			•				0.33 [0.16, 0.5
innati 2020	Depressive symptoms			:		. ⊢		2.96 2.30, 3.
ukas 2021	Depressive symptoms			:.		1		1.21 [0.73, 1.
tiles-Shields 2019	Depressive symptoms			:	· · ·			1.19 0.14, 2.
unt 2021	Depressive symptoms			: +				1.06 0.59, 1.
agöö 2014	Depressive symptoms			: F				0.87 0.47, 1.2
eng 2022	Depressive symptoms			: . '				0.84 [0.60, 1.0
u 2022 norsu 2020	Depressive symptoms							0.82 0.37, 1.3
ur 2018	Depressive symptoms Depressive symptoms			<u> </u>	_			0.66 [-0.03, 1.3
oberg 2019	Depressive symptoms							0.64 [0.34, 0.9
am 2019	Depressive symptoms				_			0.61 0.07, 1.
antani 2017	Depressive symptoms							0.58 0.27, 0.1
eyer 2019	Depressive symptoms				_			0.54 0.25, 0.1
olz 2018	Depressive symptoms				<u> </u>			0.42[-0.09, 0.9
-Refae 2021	Depressive symptoms							0.30 [-0.03, 0.0
uehiman-Senecal 2020	Depressive symptoms							0.27 [0.00, 0.
amura 2021	Depressive symptoms			1444				0.21 0.07, 0.3
Cloud 2020	Depressive symptoms							0.20 [-0.20, 0.0
ruhns 2021	Depressive symptoms			i Hannard I				0.18 -0.08, 0.4
h 2020	Depressive symptoms		1		-			0.17 -0.45, 0.1
ahne 2019	Depressive symptoms				-i i			0.16 -0.41, 0.
öhr 2021	Depressive symptoms			H-	÷			0.13 -0.22, 0.4
oepke 2015	Depressive symptoms							0.09 [-0.42, 0.0
ahne 2019	Depressive symptoms		F -		-			0.04 [-0.71, 0.]
reer 2019	Depressive symptoms				-			0.03 [-0.78, 0.1
údtke 2018	Depressive symptoms		H					-0.14 [-0.53, 0.3
akker 2018	Depressive symptoms		-	• 1				-0.34 [-0.66, -0.0
E Model (Q = 159.91, df =	$26, p < .01; l^2 = 89.6\%$: 📥				0.51 [0.30, 0.1
				;				
tolz 2018	General distress							0.49 [-0.02, 1.0
epp 2019	General distress			H-				0.02 [-0.26, 0.3
E Model (Q = 2.53, df = 1,	$p = 0.11; l^2 = 60.6\%$				3			0.20 [-0.25, 0.0
					12			
ukas 2021	Wellbeing			:	-			0.77 0.31, 1.2
agöö 2014	Wellbeing			: -	_			0.64 0.24, 1.0
eng 2022	Wellbeing				1			0.48 [0.25, 0.1
tolz 2018	Wellbeing				-			0.39 [-0.12, 0.9 0.31 [0.03, 0.9
eyer 2019 horsu 2020	Wellbeing			1				0.31 0.09, 0.5
am 2019	Wellbeing							0.25 [-0.27, 0.3
akker 2018	Wellbeing			1				0.18 -0.14, 0.5
ruhns 2021	Wellbeing							0.13 -0.14, 0.4
rvis 2019	Wellbeing		L					0.07 [-0.65, 0.1
oepke 2015	Wellbeing				•			0.05 [-0.46, 0.
-Refae 2022	Wellbeing							0.01 [-0.30, 0.3
reer 2019	Wellbeing		<u> </u>		-			-0.00 [-0.81, 0.1
unt 2021	Wellbeing			1	18. C			-1.24 [-1.72, -0.]
E Model (Q = 54.59, df = 1	$13, p < .01; l^2 = 82.8\%$		0.947 - 53	-				0.18 [-0.05, 0.4
E Multilevel Model	2			•				0.34 [0.12, 0.5
Q = 295.42, df = 61, p = 0.0	000;l ² = 89.7%)							
					-		-	
						•		
		-2	-1	0	1	2	3	4

FIGURE 4

Forest plot of the multilevel meta-analysis (main analysis) comprising all mental health outcomes and traditional meta-analyses on single outcome categories. Positive effect size estimates indicate favorable effects of an intervention (i.e., reductions of mental symptoms or increases in well-being). CI, confidence interval; DF, degree of freedom; I^2 , heterogeneity index in percentage (range: 0%–100%); Q, Cochran's Q statistic with p value.

 $Q_M(1) = 0.27$, p = .602 (see **Table 2**). Further, there was no evidence for differences in effects between populations with elevated symptoms of mental disorders compared to populations without symptoms of mental disorders (See **Supplementary Material F**).

Intervention type

As not enough studies in the category mental health promotion (n = 2) were available, we performed the moderator analysis only for treatment vs. prevention. We found no

				Confidence interval		Prediction interval						
Analysis	n	k	<i>M</i> (SMD)	95% _l	95% _u	95% _l	95% _u	p	Q	df	p(Q)	l ² (l ² _{s,} l ² ₀)
Mental health (ML)	30	62	0.34	0.12	0.56	-0.54	1.23	.002	295.42	61	<.001	86.5 (78.5, 8.0)
Anxiety symptoms (T)	19	19	0.33	0.16	0.50	-0.31	0.96	<.001	61.38	18	<.001	76.7
Depressive symptoms (T)	27	27	0.51	0.30	0.73	-0.53	1.55	<.001	159.91	26	<.001	89.6
Psychological distress (T)	2	2	0.20	-0.25	0.66	-	-	.380	2.54	1	.111	60.6
Well-being (T)	14	14	0.18	-0.05	0.42	-0.62	0.99	.126	54.59	13	<.001	82.8

TABLE 1 Results of main analyses (multilevel and traditional meta-analyses) for primary outcomes comparing mHealth interventions to enhance cognitive reappraisal with comparator conditions.

The multilevel meta-analysis on mental health indicators included anxiety symptoms, depressive symptoms, psychological distress, and well-being. For all outcomes, SMDs were calculated in a way that positive values indicate favorable effects of an intervention (i.e., reductions of mental symptoms or increases in well-being). Df, degrees of freedom; l^2 , heterogeneity index in percentage (range: 0%-100%); l^2_{s} , heterogeneity accounted for by between-study differences; l^2_{o} , heterogeneity accounted for by betwe

TABLE 2	Results of	of the	moderator	analyses	for	categorical	moderators.
---------	------------	--------	-----------	----------	-----	-------------	-------------

Analysis	n	k	M(SMD)	95%Cl _l	95%Cl _u	р			
Population type									
Clinical populations	10	22	0.28	0.28 -0.04		.083			
Non-clinical populations	20	40	0.37	0.12	0.63	.004			
$Q_M(1) = 0.27, p = .602$									
Intervention Type									
Treatment	23	45	0.39	0.12	0.65	.004			
Prevention	5	11	0.19	-0.25	0.64	.397			
$Q_M(1) = 0.73, p = .394$									
Availability of human support									
Human support available	8	16	0.50	0.15	0.85	.005			
No human support available	8	22	0.28	0.03	0.52	.026			
$Q_M(1) = 1.36, p = .243$									
Stand alone vs. combine	d								
Stand alone	7	9	0.37	0.14	0.61	.002			
Add-on	23	53	0.23	-0.16	0.61	.254			
$Q_M(1) = 0.49, p = .484$									
Control Condition									
Active comparator	14	30	0.13	-0.12	0.39	.316			
Passive comparator	23	45	0.44	0.21	0.68	<.001			
$Q_M(1) = 11.90, p = .001$									

Results for the categorical moderator variables in the multilevel model including all outcomes, i.e., anxiety symptoms, depressive symptoms, psychological distress, and well-being. Again, positive SMDs indicate positive intervention effects. We present results of omnibus moderator tests (i.e., Q_M test) along with estimates per subgroup (obtained from the multilevel model). To note, for the moderator analysis on control condition, we included all effect sizes reporting on active and passive comparators separately (nested within studies), thus, the number of effect sizes included in this analysis exceeds the number of effect sizes included in the main analysis. Further, the subgroup mental health promotion contains only two studies and was left out from the analysis on intervention type. Therefore, the number of studies in the moderator analysis is lower than in the main analysis.

 $Q_M(df)$, omnibus moderator test with degrees of freedom; *k*, number of effect sizes; *n*, number of studies; SMD, standardized mean difference, 95% Cl_u lower boundary of the 95% confidence interval; 95% Cl_u, upper boundary of the 95% confidence interval.

evidence for differences between intervention effects in treatment and prevention interventions, $Q_M(1) = 0.73$, p = .394 (see Table 2).

Proportion of cognitive reappraisal component

We found no evidence for interventions comprising a higher proportion of cognitive reappraisal to be associated with larger intervention effects, $Q_M(1) = 0.02$, p = .896.

Intervention duration

We found no evidence for more intense interventions, that is, interventions with more days, being associated with larger intervention effects, $Q_M(1) = 0.39$, p = .533.

Availability of human support

There was no evidence for a moderator effect of the availability of human support, $Q_M(1) = 1.36$, p = .243 (see Table 2).

Stand-alone versus combined interventions

Also when comparing stand-alone mHealth interventions with combined interventions (e.g., mHealth intervention with face-to-face sessions), we found no evidence for a moderator effect, $Q_M(1) = 0.49$, p = .484 (see Table 2).

Control condition

There was evidence for a moderator effect of the type of comparator condition (i.e., passive vs. active comparators) $Q_M(1) = 11.90$, p = .001. While studies using passive comparators provided evidence for a small to medium favourable effect of interventions with a cognitive reappraisal component, there was no evidence for a favourable effect when active comparators were used (see Table 2).

Sensitivity analyses

Risk of bias

We re-estimated our main analysis on mental health outcomes excluding effect sizes rated to be at least "at some concern" for risk of bias in different domains (see **Supplementary Material E** for detailed results). Excluding all effect sizes being at least at "some concern" regarding the randomization process, the analysis

				Confidence Prediction interval interval								
Risk of bias domain	n	k	M(SMD)	95% _I	95% _u	95% _l	95% _u	р	Q	df	p(Q)	² (1 ² _{5,} 1 ² ₀)
Randomization	18	38	0.42	0.13	0.70	-0.70	1.53	.004	195.24	37	<.001	92.1 (89.8, 2.4)
Deviations from intended intervention	14	31	0.47	0.10	0.84	-0.74	1.68	.014	186.22	30	<.001	94.2 (84.4, 9.8)
Missing outcome data	19	39	0.42	0.11	0.74	-0.75	1.60	.009	245.10	38	<.001	93.1 (86.7, 6.5)
Outcome measurement	4	8	0.23	-0.12	0.59	-	-	.202	53.95	7	<.001	86.4 (86.4, 0)
Selective reporting	26	55	0.35	0.10	0.59	-0.53	1.00	.005	285.21	54	<.001	61.5 (55.9, 5.6)

TABLE 3 Results of main analysis excluding effect sizes rated to be at least "at some concern" for specific risk of bias domains.

The multilevel meta-analysis on mental health included anxiety symptoms, depressive symptoms, psychological distress, and well-being. Effect-sizes that were at least 'at some concern' for the respective bias domain were excluded from these analyses. For all outcomes, SMDs were calculated in a way that positive values indicate favorable effects of an intervention (i.e., reductions of mental symptoms or increases in well-being).

Df, degrees of freedom; l^2 , heterogeneity index in percentage (range: 0%–100%); l^2_{s} , heterogeneity accounted for by between-study differences; l^2_{O} , heterogeneity accounted for by between-outcome differences; k, number of effect sizes; ML, multilevel meta-analysis, n, number of studies; Q, Cochran's Q statistic with p value; SMD, standardized mean difference; T, traditional meta-analysis; 95%, lower boundary of the 95% confidence/prediction interval; 95%, upper boundary of the 95% confidence/prediction interval.

yielded similar results, M(SMD) = 0.42, 95% CI [0.13, 0.70], p < .001. The same applied to analyses excluding effect sizes with at least some concerns in the domains of deviation from intended intervention, missing outcome data, and selective reporting. An analysis based on eight effect sizes at low risk for bias for outcome assessment provided no evidence for a favourable effect of mHealth interventions to enhance cognitive reappraisal, M(SMD) = 0.23, 95% CI [-0.12, 0.59], p = .202 (see Table 3).

Crossover RCT

We included a crossover RCT in our main analysis for which no ideal outcome data was available. However, in- and excluding this trial left our results largely unchanged, M(SMD) = 0.37, 95%CI [0.17, 0.56], p < .001, as evidenced by overlapping confidence intervals.

Condition labelling in primary studies

In a few cases, we included conditions as intervention group that were labelled as control conditions by primary study authors. Excluding these studies from our main analysis left our results unchanged, M(SMD) = 0.36, 95% CI [0.14, 0.58], p = .002.

Discussion

Main findings

With this systematic review and meta-analysis, we aimed to evaluate the efficacy of mHealth interventions comprising a component of cognitive reappraisal to enhance mental health. mHealth interventions are popular and an increasing number of programs aiming at reducing mental symptoms, preventing mental disorders, or promoting mental health become available for users. Nevertheless, the scientific evaluation of effective components is still in its beginnings. Therefore, we aimed to contribute to close this gap. We followed a mechanistic approach assuming that cognitive reappraisal, as an evidence-based therapeutic mechanism, might be a particular promising target of mHealth interventions.

During the process of study selection, it became evident that cognitive reappraisal is usually included in multi-component mHealth interventions. This means that reappraisal is one of many mHealth intervention components (e.g., behavioral exercises, psychoeducation). Only three of 30 identified studies exclusively focused on the promotion of reappraisal. Thus, this review and meta-analysis cannot provide evidence on the effects of single-component reappraisal mHealth interventions as initially intended. However, the present review provided an evidence synthesis on complex mHealth interventions including a reappraisal component.

In our main analysis, we included 62 effect sizes of 30 studies. We found evidence for a small to medium overall effect favoring mHealth interventions to enhance cognitive reappraisal over comparators across all mental health outcomes. Analyses considering single symptoms (i.e., anxiety, depression, psychological distress, and well-being) revealed a more differentiated picture. Small to medium effects in favor of mHealth interventions were found for depressive and anxiety symptoms, but there was no evidence for an effect on well-being and general psychological distress. Notably, we identified only two studies with outcomes of general psychological distress. This means that mHealth interventions might be beneficial for the reduction of depressive and anxiety symptoms only and do not succeed in the improvement of positive indicators of mental health, such as well-being.

The detected effect sizes are comparable to recent metaanalyses that found evidence for small to medium effects of mHealth interventions on depression (15, 17) and anxiety (16).

Even though the meta-analysis revealed a significant overall effect of complex mHealth interventions including a cognitive

reappraisal component on mental health, moderator analyses provided a more nuanced picture with favorable effects only being found when interventions were compared with passive but not active controls. In line with other meta-analyses of mHealth interventions (15, 16), this result suggests that the use of a digital device itself may provide psychological benefits. In this regard, the concept of a digital placebo effect has been proposed (98). Thus, the favorable overall intervention effect may reflect the rather unspecific effect of mHealth interventions.

We also investigated various other moderator variables (e.g., sociodemographic variables, availability of human support), but none of them reached significance. This indicates that complex mHealth interventions including a cognitive reappraisal component may be applicable to a broad range of users and a variety of intervention features.

Notably, we did not find evidence for mHealth interventions including cognitive reappraisal to be more effective when used to reduce mental symptoms compared to mHealth programs with a preventive focus. However, only a small amount of mHealth interventions with a focus on the prevention of mental disorders or mental health promotion were eligible for our systematic review. This is in line with findings from similar fields showing a strong focus on symptom reduction with limited evidence available for mental health promotion and prevention programs (99). Mostly, mHealth interventions targeted individuals with (at least) elevated symptoms of mental disorders, meaning that cognitive reappraisal was used for symptom reduction. The effectiveness of cognitive reappraisal components in mHealth interventions for more general population samples (i.e., prevention of mental disorder or mental health promotion) need further research. This ties in with an overall need for intensified research in the areas of mental health promotion and prevention of mental disorders (100).

In contrast to our expectations, we found no evidence for mHealth interventions with larger proportions of reappraisal promotion being associated with larger intervention effects. Consequently, we did not find evidence for a dose-response relationship between reappraisal proportion and intervention effects. First, this finding might be explained by the small proportion of cognitive reappraisal in most of the interventions (70% of the mHealth interventions included 20% or less reappraisal training). Second, we calculated the relation of the reappraisal-component relative to the total number of intervention components as the best available proxy for the intensity of reappraisal training. However, this might only insufficiently capture the intensity of reappraisal training. For example, a mHealth intervention containing one module on cognitive reappraisal next to a second module has a reappraisalproportion of 50%. However, having less training modules might not automatically result in a more intense, and in turn, effective reappraisal training. Insufficient reporting of intervention details in the included primary studies prevented a more elaborated analysis.

The absence of a specific effect of cognitive reappraisal components might be interpreted with regard to the usefulness of cognitive reappraisal itself. Some authors have started to question the usefulness of cognitive reappraisal for regulating negative emotions in comparison to other emotion regulatory and cognitive mechanisms in the past (101, 102). For example, an individual participant data component network meta-analysis (cNMA) of internet-based CBT trials for depression resulted in no additive effect of cognitive restructuring components (43).

Limitations

Our review should be interpreted in the light of its limitations. First, the included studies are limited to interventions that are provided via mobile devices such as smartphones. Therefore, we can only draw conclusions on the efficacy of cognitive reappraisal in the specific setting of mHealth and one should not generalize the findings to, for example, any digital intervention or face-toface settings. This implies that the small effects of complex mHealth interventions including a cognitive reappraisal component might be not because of the impact of reappraisal itself but arise from problems with the mobile delivery. A training of cognitive reappraisal might be better addressed in face-to-face settings than in mHealth interventions, for example because the commitment to the intervention and participants' willingness to engage in cognitive, sometimes challenging exercises might be more successful when supported and encouraged by a human being. Even if the use of mobile devices offers novel possibilities for encouragement and individualization, smartphones may sometimes fail to reach the individual and to consolidate reappraisal skills as a long-term engagement is often lacking. However, we cannot make a statement on the participants' compliance in the included mHealth interventions as data on compliance were provided rarely in the studies and were not eligible for analyses.

Moreover, during the selection process, it became apparent that many studies failed to report sufficient intervention details (i.e., training content). We can therefore not rule out that we missed mHealth interventions that have used cognitive reappraisal training but failed to report it explicitly. Vice versa, we might have overrated reappraisal in some studies because we classified studies as reappraisal intervention even if the reappraisal training was part of a complex intervention. Studies might also be heterogeneous regarding their reappraisal training components in terms of schedule and content. We might have also missed eligible studies that are ongoing or unpublished as we focused the literature search on electronic databases and did not check for grey literature or perform citation searching. Moreover, our literature search ended in March 2022 and was not updated, which might have resulted in some publications being not included in our analyses. Thus, future systematic reviews will have to update our findings based on a larger number of primary studies.

Further, there are limitations that originate from the included studies. The reviewed studies were mainly multi-component interventions, which might include active intervention components next to cognitive reappraisal. Thus, the reviewed studies did not allow us to draw conclusions about a reappraisalspecific intervention effect. In addition, information whether participants acquired reappraisal skills are lacking. We could not analyze intervention effects on reappraisal because the included studies did not evaluate reappraisal-specific outcomes. Thus, we cannot answer the question of whether the included interventions in fact enhanced cognitive reappraisal.

The risk of bias assessment points towards a high risk of bias in most of the included studies. This is due to the fact that outcomes in the studies were assessed using self-report measures and participants were aware of group assignment.

Implications and future research

Even in the light of the limitations outlined above, our findings have important implications for future research on mHealth interventions. First, more research evaluating the effects of reappraisal training via mHealth interventions are required. These are mHealth interventions consisting of an isolated training of cognitive reappraisal as well as trials with cognitive reappraisal specific outcomes. Moreover, it is important to examine whether cognitive reappraisal or its combination with other intervention components are superior in the promotion of mental health. A promising approach are dismantling studies, in which full mHealth interventions are experimentally compared with a disentangled variation of the same intervention that omits cognitive reappraisal. These studies can lead to evidence on the specific effects of single intervention components, i.e., cognitive reappraisal, and advance the research on the mechanisms of therapeutic change in mHealth interventions. Second, research on the effects and usability of mHealth interventions enhancing cognitive reappraisal skills in the real-world (i.e., effectiveness studies) should be expanded. Third, meta-analyses on individual participant data could consider Level 1-moderators (e.g., age, symptom severity) with greater statistical power, which may allow for future tailoring of interventions.

Conclusion

Our findings provide insights into the implementation and use of cognitive reappraisal training modules in mHealth interventions. Training components related to the enhancement of cognitive reappraisal have gained scientific interest in the last years and are implemented in apps and other mHealth formats for various population groups. As expected, it turned out that most of the identified mHealth interventions were multi-component interventions, in which cognitive reappraisal was promoted alongside multiple other components. We found first evidence for a small to medium favorable effect of these complex mHealth interventions that included a component of cognitive reappraisal on mental health. The favorable effects were found only when mHealth interventions were compared with passive but not active controls. There was also no evidence for a dose-response effect of reappraisal. Thus, our findings suggest that favorable effects may arise mainly from unspecific beneficial effect of mHealth interventions. Consequently, high-quality dismantling studies examining the effects of single intervention components are warranted to corroborate and further evaluate active therapeutic mechanisms in mHealth interventions such as cognitive reappraisal.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author contributions

KM: Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review and editing. SS: Conceptualization, Data curation, Methodology, Supervision, Writing – original draft, Writing – review and editing. AK: Conceptualization, Formal analysis, Methodology, Writing – review and editing. L-SP: Data curation, Writing – review and editing. OT: Conceptualization, Project administration, Supervision, Writing – review and editing. TK: Conceptualization, Project administration, Supervision, Writing – review and editing.

Funding

This project has received funding from: the State of Rhineland-Palatinate, Germany (DRZ EMA/EMI program, Leibniz Institute for Resilience Research), the European Union's Horizon 2020 research and innovation program under Grant Agreement No. 777084 (DynaMORE project) and the Deutsche Forschungsgemeinschaft (DFG Grant CRC 1193, subprojects C04 & Z03). The publication of this article was funded by the Open Access Fund of the Leibniz Association.

Acknowledgments

We wish to thank all research assistants for their contribution in the literature screening, data extraction, and quality assessment.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of

their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fdgth.2023. 1253390/full#supplementary-material **SUPPLEMENTARY MATERIAL A** Full search strategy.

SUPPLEMENTARY MATERIAL B Coding.

SUPPLEMENTARY MATERIAL C Study characteristics.

SUPPLEMENTARY MATERIAL D Proportion of cognitive reappraisal.

SUPPLEMENTARY MATERIAL E Study quality assessment.

SUPPLEMENTARY MATERIAL F Moderator analysis.

References

1. World Health Organization. The WHO special initiative for mental health (2019-2023): universal health coverage for mental health; technical documents. (2019).

2. Fairburn CG, Patel V. The impact of digital technology on psychological treatments and their dissemination. *Behav Res Ther.* (2017) 88:19–25. doi: 10.1016/j. brat.2016.08.012

3. Petrie K, Proudfoot J, Clarke J, Birch M-R, Christensen H. Smartphones for smarter delivery of mental health programs: a systematic review. *J Med Internet Res.* (2013) 15(11):e247. doi: 10.2196/jmir.2791

4. Heron KE, Smyth JM. Ecological momentary interventions: incorporating mobile technology into psychosocial and health behaviour treatments. *Br J Health Psychol.* (2010) 15(Pt 1):1–39. doi: 10.1348/135910709X466063

5. Donker T, Blankers M, Hedman E, Ljótsson B, Petrie K, Christensen H. Economic evaluations of internet interventions for mental health: a systematic review. *Psychol Med.* (2015) 45(16):3357–76. doi: 10.1017/S0033291715001427

6. Paganini S, Teigelkötter W, Buntrock C, Baumeister H. Economic evaluations of internet- and mobile-based interventions for the treatment and prevention of depression: a systematic review. *J Affect Disord.* (2018) 225:733–55. doi: 10.1016/j. jad.2017.07.018

7. Rathbone AL, Clarry L, Prescott J. Assessing the efficacy of mobile health apps using the basic principles of cognitive behavioral therapy: systematic review. J Med Internet Res. (2017) 19(11):e399. doi: 10.2196/jmir.8598

8. Rathbone AL, Prescott J. The use of mobile apps and SMS messaging as physical and mental health interventions: systematic review. *J Med Internet Res.* (2017) 19(8): e295. doi: 10.2196/jmir.7740

9. Wang K, Varma DS, Prosperi M. A systematic review of the effectiveness of mobile apps for monitoring and management of mental health symptoms or disorders. *J Psychiatr Res.* (2018) 107:73–8. doi: 10.1016/j.jpsychires.2018. 10.006

10. Wickersham A, Petrides PM, Williamson V, Leightley D. Efficacy of mobile application interventions for the treatment of post-traumatic stress disorder: a systematic review. *Digit Health.* (2019) 5:1–11. doi: 10.1177/2055207619842986

11. Serrano-Ripoll MJ, Zamanillo-Campos R, Fiol-DeRoque MA, Castro A, Ricci-Cabello I. Impact of smartphone app-based psychological interventions for reducing depressive symptoms in people with depression: systematic literature review and meta-analysis of randomized controlled trials. *JMIR Mhealth Uhealth.* (2022) 10(1): e29621. doi: 10.2196/29621

12. Lecomte T, Potvin S, Corbière M, Guay S, Samson C, Cloutier B, et al. Mobile apps for mental health issues: meta-review of meta-analyses. *JMIR Mhealth Uhealth.* (2020) 8(5):e17458. doi: 10.2196/17458

13. Purgato M, Uphoff E, Singh R, Thapa Pachya A, Abdulmalik J, van Ginneken N. Promotion, prevention and treatment interventions for mental health in low- and middle-income countries through a task-shifting approach. *Epidemiol Psychiatr Sci.* (2020) 29:e150. doi: 10.1017/S204579602000061X

14. Uphoff E, Robertson L, Cabieses B, Villalón FJ, Purgato M, Churchill R, et al. An overview of systematic reviews on mental health promotion, prevention, and treatment of common mental disorders for refugees, asylum seekers, and internally displaced persons. *Cochrane Database Syst Rev.* (2020) 9(9):CD013458. doi: 10.1002/14651858.CD013458.pub2

15. Firth J, Torous J, Nicholas J, Carney R, Pratap A, Rosenbaum S, et al. The efficacy of smartphone-based mental health interventions for depressive symptoms: a meta-analysis of randomized controlled trials. *World Psychiatry.* (2017) 16 (3):287–98. doi: 10.1002/wps.20472

16. Firth J, Torous J, Nicholas J, Carney R, Rosenbaum S, Sarris J. Can smartphone mental health interventions reduce symptoms of anxiety? A meta-analysis of randomized controlled trials. *J Affect Disord.* (2017) 218:15–22. doi: 10.1016/j.jad. 2017.04.046

17. Senanayake B, Wickramasinghe SI, Chatfield MD, Hansen J, Edirippulige S, Smith AC. Effectiveness of text messaging interventions for the management of depression: a systematic review and meta-analysis. *J Telemed Telecare*. (2019) 25 (9):513–23. doi: 10.1177/1357633X19875852

18. Versluis A, Verkuil B, Spinhoven P, van der Ploeg MM, Brosschot JF. Changing mental health and positive psychological well-being using ecological momentary interventions: a systematic review and meta-analysis. *J Med Internet Res.* (2016) 18 (6):e152. doi: 10.2196/jmir.5642

19. Deady M, Choi I, Calvo RA, Glozier N, Christensen H, Harvey SB. Ehealth interventions for the prevention of depression and anxiety in the general population: a systematic review and meta-analysis. *BMC Psychiatry.* (2017) 17 (1):310. doi: 10.1186/s12888-017-1473-1

20. Eisenstadt M, Liverpool S, Infanti E, Ciuvat RM, Carlsson C. Mobile apps that promote emotion regulation, positive mental health, and well-being in the general population: systematic review and meta-analysis. *JMIR Ment Health*. (2021) 8(11): e31170. doi: 10.2196/31170

21. Seegan PL, Miller MJ, Heliste JL, Fathi L, McGuire JF. Efficacy of stand-alone digital mental health applications for anxiety and depression: a meta-analysis of randomized controlled trials. *J Psychiatr Res.* (2023) 164:171–83. doi: 10.1016/j. jpsychires.2023.06.019

22. Coulon SM, Monroe CM, West DS. A systematic, multi-domain review of mobile smartphone apps for evidence-based stress management. *Am J Prev Med.* (2016) 51(1):95–105. doi: 10.1016/j.amepre.2016.01.026

23. Bakker D, Kazantzis N, Rickwood D, Rickard N. Mental health smartphone apps: review and evidence-based recommendations for future developments. *JMIR Ment Health.* (2016) 3(1):e7. doi: 10.2196/mental.4984

24. Tomlinson M, Rotheram-Borus MJ, Swartz L, Tsai AC. Scaling up mHealth: where is the evidence? *PLoS Med.* (2013) 10(2):e1001382. doi: 10.1371/journal. pmed.1001382

25. Larsen ME, Huckvale K, Nicholas J, Torous J, Birrell L, Li E, et al. Using science to sell apps: evaluation of mental health app store quality claims. *NPJ Digit Med.* (2019) 2(1):18. doi: 10.1038/s41746-019-0093-1

26. Wasil AR, Venturo-Conerly KE, Shingleton RM, Weisz JR. A review of popular smartphone apps for depression and anxiety: assessing the inclusion of evidence-based content. *Behav Res Ther.* (2019) 123:103498. doi: 10.1016/j.brat.2019.103498

27. Martinengo L, Stona A-C, Griva K, Dazzan P, Pariante CM, Wangenheim Fv, et al. Self-guided cognitive behavioral therapy apps for depression: systematic assessment of features, functionality, and congruence with evidence. *J Med Internet Res.* (2021) 23(7):e27619. doi: 10.2196/27619

28. Gross JJ. Emotion regulation: affective, cognitive, and social consequences. *Psychophysiology*. (2002) 39(3):281–91. doi: 10.1017/S0048577201393198

29. McRae K, Ciesielski B, Gross JJ. Unpacking cognitive reappraisal: goals, tactics, and outcomes. *Emotion*. (2012) 12(2):250–5. doi: 10.1037/a0026351

30. McRae K, Gross JJ. Emotion regulation. *Emotion*. (2020) 20(1):1–9. doi: 10.1037/emo0000703

31. Beck AT, Dozois DJA. Cognitive therapy: current status and future directions. *Annu Rev Med.* (2011) 62:397–409. doi: 10.1146/annurev-med-052209-100032

32. Clark DA. Cognitive restructuring. In: Hofmann SG, editors. *The wiley handbook of cognitive behavioral therapy.* Chichester, UK: John Wiley & Sons, Ltd (2013). p. 1–22.

33. Aldao A, Nolen-Hoeksema S. Specificity of cognitive emotion regulation strategies: a transdiagnostic examination. *Behav Res Ther.* (2010) 48(10):974–83. doi: 10.1016/j.brat.2010.06.002

34. Garnefski N, Kraaij V. Relationships between cognitive emotion regulation strategies and depressive symptoms: a comparative study of five specific samples. *Pers Individ Dif.* (2006) 40(8):1659–69. doi: 10.1016/j.paid.2005.12.009

35. Hu T, Zhang D, Wang J, Mistry R, Ran G, Wang X. Relation between emotion regulation and mental health: a meta-analysis review. *Psychol Rep.* (2014) 114 (2):341–62. doi: 10.2466/03.20.PR0.114k22w4

36. LeMoult J, Gotlib IH. Depression: a cognitive perspective. Clin Psychol Rev. (2019) 69:51-66. doi: 10.1016/j.cpr.2018.06.008

37. Haga SM, Kraft P, Corby E-K. Emotion regulation: antecedents and well-being outcomes of cognitive reappraisal and expressive suppression in cross-cultural samples. *Journal of Happiness Studies: An Interdisciplinary Forum on Subjective Well-Being.* (2009) 10(3):271–91. doi: 10.1007/s10902-007-9080-3

38. Riepenhausen A, Wackerhagen C, Reppmann ZC, Deter H-C, Kalisch R, Veer IM, et al. Positive cognitive reappraisal in stress resilience, mental health, and wellbeing: a comprehensive systematic review. *Emot Rev.* (2022) 14(4):310–31. doi: 10. 1177/17540739221114642

39. Lorenzo-Luaces L, German RE, DeRubeis RJ. It's complicated: the relation between cognitive change procedures, cognitive change, and symptom change in cognitive therapy for depression. *Clin Psychol Rev.* (2015) 41:3–15. doi: 10.1016/j. cpr.2014.12.003

40. Hofmann SG, Meuret AE, Rosenfield D, Suvak MK, Barlow DH, Gorman JM, et al. Preliminary evidence for cognitive mediation during cognitive-behavioral therapy of panic disorder. *J Consult Clin Psychol.* (2007) 75(3):374–9. doi: 10.1037/0022-006X.75.3.374

41. Kleim B, Grey N, Wild J, Nussbeck FW, Stott R, Hackmann A, et al. Cognitive change predicts symptom reduction with cognitive therapy for posttraumatic stress disorder. *J Consult Clin Psychol.* (2013) 81(3):383–93. doi: 10.1037/a0031290

42. López-López JA, Davies SR, Caldwell DM, Churchill R, Peters TJ, Tallon D, et al. The process and delivery of CBT for depression in adults: a systematic review and network meta-analysis. *Psychol Med.* (2019) 49(12):1937–47. doi: 10.1017/ S003329171900120X

43. Furukawa TA, Suganuma A, Ostinelli EG, Andersson G, Beevers CG, Shumake J, et al. Dismantling, optimising, and personalising internet cognitive behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data. *Lancet Psychiatry.* (2021) 8(6):500–11. doi: 10.1016/S2215-0366(21)00077-8

44. Cuijpers P, Cristea IA, Karyotaki E, Reijnders M, Hollon SD. Component studies of psychological treatments of adult depression: a systematic review and meta-analysis. *Psychother Res.* (2019) 29(1):15–29. doi: 10.1080/10503307.2017. 1395922

45. Pompoli A, Furukawa TA, Efthimiou O, Imai H, Tajika A, Salanti G. Dismantling cognitive-behaviour therapy for panic disorder: a systematic review and component network meta-analysis. *Psychol Med.* (2018) 48(12):1945–53. doi: 10.1017/S0033291717003919

46. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Br Med J.* (2021) 372:n71. doi: 10.1136/bmj.n71

47. Veritas Health Innovation. Covidence—better systematic review management. (2019).

48. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev.* (2016) 5(1):210. doi: 10.1186/s13643-016-0384-4

49. Kalisch R, Müller MB, Tüscher O. A conceptual framework for the neurobiological study of resilience. *Behav Brain Sci.* (2015) 38:e92. doi: 10.1017/S0140525X1400082X

50. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med.* (2001) 16(9):606–13. doi: 10.1046/j.1525-1497. 2001.016009606.x

51. Garnefski N, Kraaij V. The cognitive emotion regulation questionnaire. *Eur J Psychol Assess.* (2007) 23(3):141–9. doi: 10.1027/1015-5759.23.3.141

52. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. *Br Med J.* (2019) 366: 14898. doi: 10.1136/bmj.14898

53. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. (2008) 61(10):991–6. doi: 10.1016/j.jclinepi.2007.11.010

54. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics.* (1994) 50(4):1088–101. doi: 10.2307/2533446

55. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.3 (updated

February 2022). Chichester, UK: Cochrane (2022). Available at: www.training. cochrane.org/handbook

56. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing (2022). Available from: https://www. R-project.org/

57. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. (2010) 36(3):1-48. doi: 10.18637/jss.v036.i03

58. Assink M, Wibbelink CJM. Fitting three-level meta-analytic models in R: a stepby-step tutorial. *TQMP*. (2016) 12(3):154–74. doi: 10.20982/tqmp.12.3.p154

59. Beck AT, Steer RA, Brown G. Beck depression inventory–II (BDI-II) [Database record]. APA PsycTests. (1996). https://doi.org/10.1037/t00742-000

60. Sedgwick P. Meta-analyses: what is heterogeneity? Br Med J. (2015) 350:h1435. doi: 10.1136/bmj.h1435

61. Ahorsu DK, Lin C-Y, Imani V, Carlbring P, Nygårdh A, Broström A, et al. Testing an app-based intervention to improve insomnia in patients with epilepsy: a randomized controlled trial. *Epilepsy Behav.* (2020) 112:107371. doi: 10.1016/j. yebeh.2020.107371

62. Al-Refae M, Al-Refae A, Munroe M, Sardella NA, Ferrari M. A self-compassion and mindfulness-based cognitive Mobile intervention (serene) for depression, anxiety, and stress: promoting adaptive emotional regulation and wisdom. *Front Psychol.* (2021) 12:648087. doi: 10.3389/fpsyg.2021.648087

63. Bakker D, Kazantzis N, Rickwood D, Rickard N. A randomized controlled trial of three smartphone apps for enhancing public mental health. *Behav Res Ther.* (2018) 109:75–83. doi: 10.1016/j.brat.2018.08.003

64. Bruehlman-Senecal E, Hook CJ, Pfeifer JH, FitzGerald C, Davis B, Delucchi KL, et al. Smartphone app to address loneliness among college students: pilot randomized controlled trial. *JMIR Ment Health.* (2020) 7(10):e21496. doi: 10.2196/21496

65. Bruhns A, Lüdtke T, Moritz S, Bücker L. A Mobile-based intervention to increase self-esteem in students with depressive symptoms: randomized controlled trial. *JMIR Mhealth Uhealth*. (2021) 9(7):e26498. doi: 10.2196/26498

66. Dagöö J, Asplund RP, Bsenko HA, Hjerling S, Holmberg A, Westh S, et al. Cognitive behavior therapy versus interpersonal psychotherapy for social anxiety disorder delivered via smartphone and computer: a randomized controlled trial. *J Anxiety Disord.* (2014) 28(4):410–7. doi: 10.1016/j.janxdis.2014.02.003

67. Dahne J, Collado A, Lejuez CW, Risco CM, Diaz VA, Coles L, et al. Pilot randomized controlled trial of a spanish-language behavioral activation mobile app (japtívate!) for the treatment of depressive symptoms among United States latinx adults with limited english proficiency. *J Affect Disord*. (2019) 250:210–7. doi: 10. 1016/j.jad.2019.03.009

68. Dahne J, Lejuez CW, Diaz VA, Player MS, Kustanowitz J, Felton JW, et al. Pilot randomized trial of a self-help behavioral activation mobile app for utilization in primary care. *Behav Ther.* (2019) 50(4):817–27. doi: 10.1016/j.beth.2018.12.003

69. Depp CA, Perivoliotis D, Holden J, Dorr J, Granholm EL. Single-session mobileaugmented intervention in serious mental illness: a three-arm randomized controlled trial. *Schizophr Bull.* (2019) 45(4):752–62. doi: 10.1093/schbul/sby135

70. Greer JA, Jacobs J, Pensak N, MacDonald JJ, Fuh C-X, Perez GK, et al. Randomized trial of a tailored cognitive-behavioral therapy mobile application for anxiety in patients with incurable cancer. *Oncologist.* (2019) 24(8):1111–20. doi: 10. 1634/theoncologist.2018-0536

71. Ham K, Chin S, Suh YJ, Rhee M, Yu E-S, Lee HJ, et al. Preliminary results from a randomized controlled study for an app-based cognitive behavioral therapy program for depression and anxiety in cancer patients. *Front Psychol.* (2019) 10:1592. doi: 10. 3389/fpsyg.2019.01592

72. Hunt M, Miguez S, Dukas B, Onwude O, White S. Efficacy of zemedy, a mobile digital therapeutic for the self-management of irritable bowel syndrome: crossover randomized controlled trial. *JMIR Mhealth Uhealth.* (2021) 9(5):e26152. doi: 10. 2196/26152

73. Hur J-W, Kim B, Park D, Choi S-W. A scenario-based cognitive behavioral therapy mobile app to reduce dysfunctional beliefs in individuals with depression: a randomized controlled trial. *Telemedicine and e-Health*. (2018) 24(9):710–6. doi: 10. 1089/tmi.2017.0214

74. Imamura K, Tran TTT, Nguyen HT, Sasaki N, Kuribayashi K, Sakuraya A, et al. Effect of smartphone-based stress management programs on depression and anxiety of hospital nurses in Vietnam: a three-arm randomized controlled trial. *Sci Rep.* (2021) 11(1):11353. doi: 10.1038/s41598-021-90320-5

75. Sasaki N, Imamura K, Tran TTT, Nguyen HT, Kuribayashi K, Sakuraya A, et al. Effects of smartphone-based stress management on improving work engagement among nurses in Vietnam: secondary analysis of a three-arm randomized controlled trial. *J Med Internet Res.* (2021) 23(2):e20445. doi: 10.2196/20445

76. Jannati N, Mazhari S, Ahmadian L, Mirzaee M. Effectiveness of an app-based cognitive behavioral therapy program for postpartum depression in primary care: a randomized controlled trial. *Int J Med Inform.* (2020) 141:104145. doi: 10.1016/j. ijmedinf.2020.104145

77. Jarvis MA, Padmanabhanunni A, Chipps J. An evaluation of a low-intensity cognitive behavioral therapy mHealth-supported intervention to reduce loneliness

in older people. Int J Environ Res Public Health. (2019) 16(7):1305. doi: 10.3390/ ijerph16071305

78. Liu H, Peng H, Song X, Xu C, Zhang M. Using AI chatbots to provide self-help depression interventions for university students: a randomized trial of effectiveness. *Internet Interv.* (2022) 27:100495. doi: 10.1016/j.invent.2022.100495

79. Lüdtke T, Westermann S, Pult LK, Schneider BC, Pfuhl G, Moritz S. Evaluation of a brief unguided psychological online intervention for depression: a controlled trial including exploratory moderator analyses. *Internet Interv.* (2018) 13:73–81. doi: 10. 1016/j.invent.2018.06.004

80. Lukas CA, Eskofier B, Berking M. A gamified smartphone-based intervention for depression: randomized controlled pilot trial. *JMIR Ment Health*. (2021) 8(7):e16643. doi: 10.2196/16643

81. Mantani A, Kato T, Furukawa TA, Horikoshi M, Imai H, Hiroe T, et al. Smartphone cognitive behavioral therapy as an adjunct to pharmacotherapy for refractory depression: randomized controlled trial. *J Med Internet Res.* (2017) 19 (11):e373. doi: 10.2196/jmir.8602

82. Mantani A, Kato T, Furukawa TA, Horikoshi M, Imai H, Hiroe T, et al. Correction: smartphone cognitive behavioral therapy as an adjunct to pharmacotherapy for refractory depression: randomized controlled trial. *J Med Internet Res.* (2018) 20(8):e11702. doi: 10.2196/11702

83. Furukawa TA, Horikoshi M, Fujita H, Tsujino N, Jinnin R, Kako Y, et al. Cognitive and behavioral skills exercises completed by patients with major depression during smartphone cognitive behavioral therapy: secondary analysis of a randomized controlled trial. *JMIR Ment Health*. (2018) 5(1):e4. doi: 10.2196/mental. 9092

84. Imai H, Yamada M, Inagaki M, Watanabe N, Chino B, Mantani A, et al. Behavioral activation contributed to the total reduction of depression symptoms in the smartphone-based cognitive behavioral therapy: a secondary analysis of a randomized, controlled trial. *Innov Clin Neurosci.* (2020) 17(7-9):21–5.

85. McCloud T, Jones R, Lewis G, Bell V, Tsakanikos E. Effectiveness of a mobile app intervention for anxiety and depression symptoms in university students: randomized controlled trial. *JMIR Mhealth Uhealth.* (2020) 8(7):e15418. doi: 10.2196/15418

86. Meyer B, Weiss M, Holtkamp M, Arnold S, Brückner K, Schröder J, et al. Effects of an epilepsy-specific internet intervention (emyna) on depression: results of the ENCODE randomized controlled trial. *Epilepsia*. (2019) 60(4):656–68. doi: 10.1111/epi.14673

87. Moberg C, Niles A, Beermann D. Guided self-help works: randomized waitlist controlled trial of Pacifica, a mobile app integrating cognitive behavioral therapy and mindfulness for stress, anxiety, and depression. *J Med Internet Res.* (2019) 21 (6):e12556. doi: 10.2196/12556

88. Newman MG, Jacobson NC, Rackoff GN, Bell MJ, Taylor CB. A randomized controlled trial of a smartphone-based application for the treatment of anxiety. *Psychother Res.* (2021) 31(4):443–54. doi: 10.1080/10503307.2020.1790688

89. Oh J, Jang S, Kim H, Kim J-J. Efficacy of mobile app-based interactive cognitive behavioral therapy using a chatbot for panic disorder. *Int J Med Inform.* (2020) 140:104171. doi: 10.1016/j.ijmedinf.2020.104171

90. Roepke AM, Jaffee SR, Riffle OM, McGonigal J, Broome R, Maxwell B. Randomized controlled trial of SuperBetter, a smartphone-based/internet-based self-help tool to reduce depressive symptoms. *Games Health J.* (2015) 4(3):235–46. doi: 10.1089/g4h.2014.0046

91. Röhr S, Jung FU, Pabst A, Grochtdreis T, Dams J, Nagl M, et al. A self-help app for Syrian refugees with posttraumatic stress (sanadak): randomized controlled trial. *JMIR Mhealth Uhealth*. (2021) 9(1):e24807. doi: 10.2196/24807

92. Stiles-Shields C, Montague E, Kwasny MJ, Mohr DC. Behavioral and cognitive intervention strategies delivered via coached apps for depression: pilot trial. *Psychol Serv.* (2019) 16(2):233–8. doi: 10.1037/ser0000261

93. Stolz T, Schulz A, Krieger T, Vincent A, Urech A, Moser C, et al. A mobile app for social anxiety disorder: a three-arm randomized controlled trial comparing mobile and PC-based guided self-help interventions. *J Consult Clin Psychol.* (2018) 86 (6):493–504. doi: 10.1037/ccp0000301

94. Zeng Y, Guo Y, Ho RTH, Zhu M, Zeng C, Monroe-Wise A, et al. Positive coping as a mediator of mobile health intervention effects on quality of life among people living with HIV: secondary analysis of the randomized controlled trial Run4Love. *J Med Internet Res.* (2022) 24(2):e25948. doi: 10.2196/25948

95. Zhu M, Cai W, Li L, Guo Y, Monroe-Wise A, Li Y, et al. Mediators of intervention effects on depressive symptoms among people living with HIV: secondary analysis of a mobile health randomized controlled trial using latent growth curve modeling. *JMIR Mhealth Uhealth.* (2019) 7(11):e15489. doi: 10.2196/15489.

96. Watts S, Mackenzie A, Thomas C, Griskaitis A, Mewton L, Williams A, et al. CBT for depression: a pilot RCT comparing mobile phone vs. Computer. *BMC Psychiatry.* (2013) 13(1):49. doi: 10.1186/1471-244X-13-49

97. Christoforou M, Sáez Fonseca JA, Tsakanikos E. Two novel cognitive behavioral therapy-based Mobile apps for agoraphobia: randomized controlled trial. *J Med Internet Res.* (2017) 19(11):e398. doi: 10.2196/jmir.7747

98. Stalujanis E, Neufeld J, Glaus Stalder M, Belardi A, Tegethoff M, Meinlschmidt G. Induction of efficacy expectancies in an ambulatory smartphone-based digital placebo mental health intervention: randomized controlled trial. *JMIR Mhealth Uhealth.* (2021) 9(2):e20329. doi: 10.2196/20329

99. Schäfer SK, Kunzler AM, Lindner S, Broll J, Stoll M, Stoffers-Winterling J, et al. Transdiagnostic psychosocial interventions to promote mental health in forcibly displaced persons: a systematic review and meta-analysis. *Eur J Psychotraumatol.* (2023) 14(2):2196762. doi: 10.1080/20008066.2023.2196762

100. Singh V, Kumar A, Gupta S. Mental health prevention and promotion-A narrative review. *Front Psychiatry.* (2022) 13:898009. doi: 10.3389/fpsyt.2022. 898009

101. Ehret AM, Joormann J, Berking M. Self-compassion is more effective than acceptance and reappraisal in decreasing depressed mood in currently and formerly depressed individuals. *J Affect Disord.* (2018) 226:220–6. doi: 10.1016/j. jad.2017.10.006

102. Krafft J, Haeger JA, Levin ME. Comparing cognitive fusion and cognitive reappraisal as predictors of college student mental health. *Cogn Behav Ther.* (2019) 48(3):241–52. doi: 10.1080/16506073.2018.1513556